“The present predicament has uncovered some structural weaknesses while in the EU’s medicines supply chain in addition to a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides mentioned. She suggested that provide chain troubles be tackled within an EU pharmaceutical tactic predicted for being released